)
Visual
test
Ekso Bionics
Ekso Bionics (EKSO) investor relations material
Ekso Bionics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary28 Oct, 2025
Executive summary
Focus on advanced robotics to enhance, amplify, and restore human function, with a broad product portfolio targeting both enterprise and personal health markets.
Revenue for Q3 2025 increased 2% year-over-year to $4.2M, rebounding 105% sequentially, driven by higher Enterprise Health device sales in the Americas, partially offset by lower EMEA sales.
Gross margin improved to 60.3% from 53% in Q3 2024, reflecting favorable product mix and lower device costs.
Net loss for Q3 2025 was $1.4M, a 31% improvement from Q3 2024.
Recent expansion into personal health with the acquisition of Indego and CMS reimbursement approval for exoskeletons.
Significant events and developments
CMS approved Ekso Indego Personal for $91K lump sum reimbursement effective April 1, 2024, with the first claim approved in Q2 2024 and a growing pipeline of claims.
Named National Seating & Mobility as exclusive U.S. distributor in Q1-2025 and Bionic P & O as first orthotic/prosthetic distributor in Q2-2025.
Launched eksoUniversity in Q2-2025, offering CEU courses for neurological physical therapists and delivered first CEU certification.
Acceptance into NVIDIA Connect Program, advancing AI-powered capabilities and building a foundation model for human motion.
Initiated exploration of strategic transactions, including possible acquisition or sale of business lines.
Outlook and guidance
Anticipates meaningful revenue growth from personal health segment due to CMS reimbursement and expanded distribution partnerships.
Ongoing innovation in AI integration and product development expected to drive future growth.
Management expects operating losses and negative cash flows to continue, with current cash projected to fund operations into Q1 2026; additional financing is being sought.
Majority of 2025 revenue expected from Enterprise Health, with Personal Health sales ramping up as CMS reimbursement processes mature.
Focus remains on executing growth strategy and resource management, with active exploration of strategic transactions.
Strategic transaction rationale
Sustainability of Q3 expense reductions?
Cash runway and funding strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- BETS
Q4 2025 revenue dipped 1% and EBIT fell 24%, but full-year revenue rose 8%. - ALMA
Revenue up 4.6% to €327.1M, digital share 85.9%, profit and cash flow improved. - TMCV
Q2 FY26 delivered double-digit margin growth, record cash flow, and strong market momentum. - DANSKE
Record profit, strong credit quality, and 100% payout; 2026 outlook remains positive. - GREENPLY
Q3 FY26 delivered strong revenue growth but lower profit, with major MDF expansion announced. - KRO
Q1 2025 net income surged to $18.1M on higher TiO2 sales, improved margins, and LPC integration. - WALL
Profit after tax more than tripled to SEK 2,564 million, with net asset value per share up 8%. - TMCVQ3 FY26 delivered 17% revenue growth, 12.7% EBITDA margin, and strong cash flow.
- SHL
Imaging and therapy growth drove 3.8% Q1 revenue; 2026 outlook and EPS guidance confirmed. - SAAB
Record order backlog and double-digit growth across all segments fueled strong 2025 results.
Next Ekso Bionics earnings date
Q4 20254 Mar, 2026
Ekso Bionics
Next Ekso Bionics earnings date
Q4 20254 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Ekso Bionics Holdings Inc. is a company that develops and manufactures wearable exoskeletons designed to enhance human mobility and strength. Its core products include robotic exoskeletons used in rehabilitation and industrial applications. In healthcare, Ekso Bionics provides solutions that help patients with neurological conditions or injuries to regain mobility through assisted walking. The company's exoskeletons are also used in industrial settings to reduce worker fatigue and prevent injuries by augmenting human strength and endurance during heavy lifting and repetitive tasks. The company is headquartered in Richmond, California, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage